An observational study in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), sponsored by Royal Marsden NHS Foundation Trust. Active, not recruiting at 12 sites in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 14th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18–100 · Men only · Healthy volunteers
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in Canada, United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 2000; this study’s year is marked. 2 started in 2023.
This study's enrollment of 170 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 14 interventional studies, 100 across the 7 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
4 of the studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06638541Royal Marsden NHS Foundation TrustDose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions | 2027-01-01 |
| NCT06019676Royal Marsden NHS Foundation TrustImpact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | 2027-04-01 |
| NCT07870707Royal Marsden NHS Foundation TrustProstate Cancer in UK Prisons: A Retrospective Data Analysis | 2027-08-03 |
| NCT07741929Royal Marsden NHS Foundation TrustPatient and Provider Perspectives on Genetic Risk Profiling | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ADAPT study is an observational study of apalutamide, which can be given to patients with hormone sensitive metastatic prostate cancer as standard of care. The clinical decision for patients to have apalutamide as part of their management plan will be decided by the clinician. The patient will only be approached about the ADAPT study if they decide they want to have apalutamide as part of their management.
The aims of the ADAPT study include documenting the biochemical effectiveness, as determined by the Prostate-Specific Antigen (PSA) and impact of apaluatmide on health related quality of life. The blood test for PSA is regularly monitored as standard of care.
Additionally, the impact of apalutamide on fatigue, cognitive function, patients reported outcomes, health related quality of life will be evaluated using patient questionnaires answered at defined timepoints. The questionnaires will be sent either electronically or via post at week 12, 24, 36, 48, 72 and 104 weeks after commencement of apalutamide.
Currently, the majority of data regarding tolerability and biochemical response to apalutamide has been from large phase III trials, where there are strict eligibility criteria. Real-world data as from the ADAPT study can provide valuable complementary data to randomised controlled trials, which can be used to address the 'generalizability' limitations of randomised control trials and can provide evidence on the external validity of their findings. This information can advance knowledge of patterns of care, treatment effectiveness and side-effects and inform clinical practice to improve outcomes.
Males 18 years of age or older, with metastatic hormone sensitive prostate cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Undetectable PSA rate (defined as PSA <0.2ng/ml by end of year 1 and year 2) in mHSPC patients receiving apalutamide
Time frame: August 2023 - April 2027
The impact of apalutamide on fatigue, assessed using patient-reported Brief Fatigue Inventory questionnaire
Time frame: August 2023 - April 2027
The impact of apalutamide on cognitive function, using patient-reported FACT-Cog questionnaire
Time frame: August 2023 - April 2027
The impact of apalutamide on health-related quality of life, using patient-reported EQ-5D-5L questionnaire
Time frame: August 2023 - April 2027
Health care professional experience on the use of apalutamide, assessed using Health Care Professional Questionnaire
Time frame: August 2023 - April 2027
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Apr 2027, 42 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 42 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →